Buprenophine

• Narcotics
• Analgesics, Opioid
• Narcotic Antagonists
• ATC:N02AE01
• ATC:N07BC01

• Buprenex
• Buprenophine
• Buprenorfina [Inn-Spanish]
• Buprenorphine Hcl
• Buprenorphinum [Inn-Latin]
• Subutex
• Temgesic

• No information avaliable

C₂₉H₄₁NO₄

http://www.rxlist.com/cgi/generic3/suboxone.htm

Buprenophine FDA

No information avaliable

467.64 g/mol

No information avaliable

No information avaliable

Solid

5.096

Tablet (sublingual)

For the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence.

Buprenorphine is a synthetic opioid analgesic and thebaine derivative, with a longer duration of action than morphine. Buprenorphine interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, buprenorphine exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Buprenorphine may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Buprenorphine depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.

31% bioavailability (sublingual)

Manifestations of acute overdose include pinpoint pupils, sedation, hypotension, respiratory depression and death.

Humans and other mammals